title: [Laboratory diagnosis of Fabry disease: historical perspectives and recent breakthroughs].
abstract: Due to its high sensitivity and specificity, determination of the c-galactosidase A activity in leukocytes is the gold standard to confirm the diagnosis of Fabry disease in hemizygous moles. In contrast, heterozygous females cannot be dependably diagnosed by this method and genotyping should always be carried out. Two recent breakthroughs have contributed to the rise of screening programs for Fabry disease: first, the use of filter papers to collect blood or urine spots from individuals in at-risk populations for Fabry disease, second, the development of moss spectrometry Substrate accumulation and enzyme activity can be measured on urine and blood samples, respectively Moss spectrometry allows the qualitative and quantitative determination of the accumulation of the undegraded substrate (globotriaosylceromide) in urine, but also the measurement of enzyme activities in blood samples for the simultaneous diagnosis of several inborn errors of metabolism, among which lysosomal storage diseases and in particular Fabry disease.
authors.affiliation: Groupe de Chimie Analytique de Paris-Sud, EA 4041-IFR 141, Faculté de Pharmacie Paris XI, Châtenay-Malabry, France.
authors.forename: Éric
authors.initials: É
authors.lastname: Caudron
authors.forename: Sandrine
authors.initials: S
authors.lastname: Roy
authors.forename: Dominique P
authors.initials: DP
authors.lastname: Germain
authors.forename: Pierre
authors.initials: P
authors.lastname: Chaminade
authors.forename: Patrice
authors.initials: P
authors.lastname: Prognon
mesh_terms: D000795:Fabry Disease / Q000175:diagnosis* / Q000235:genetics; D006801:Humans; D013058:Mass Spectrometry; D014281:Trihexosylceramides / Q000032:analysis / Q000737:chemistry
chemical_list: D014281:Trihexosylceramides; C018549:globotriaosylceramide